• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Peter Marks Envisions New Development Model for Gene Therapies

Peter Marks Envisions New Development Model for Gene Therapies

April 11, 2022

To expand the field of gene therapy, Peter Marks, director of the FDA’s Center for Biologics Evaluation (CBER), believes that the current clinical development framework is in need of rethinking in terms of trial design, endpoints, communication and other areas.

As it stands now, gene therapy developers commonly refer to the clinical development framework for small-molecule drugs, Marks wrote in an editorial published in Expert Opinion on Biological Therapy. While many components of this framework apply to gene therapies — good manufacturing practices (GMP), understanding nonclinical aspects of the investigational drug and demonstrating safety and effectiveness, for instance — other aspects of gene therapies might be better served by other models, the CBER chief believes.

Marks posed that greater use of novel trial designs and endpoints, global regulatory harmonization, standardized manufacturing processes and improved communication with regulators would have a big impact on getting more gene therapies to market.

Marks believes that sponsors should consider the use of Bayesian clinical trial designs that include reassessments of therapeutic benefit probability as each patient goes through the trial process, as these measures can help to lower the number of participants needed in gene therapy trials and the small pools of rare disease patients that can make enrollment a struggle.

Additionally, because current gene therapies use a device-like “vector backbone,” most often an adeno-associated virus or lentivirus, to deliver an artificial gene, Marks thinks that the reuse of backbone-related information should be considered, as appropriate, for other gene therapies in development. Successfully doing this could accelerate development for multiple products.

Access Marks’ article here: https://bit.ly/3NPD1Vv.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing